Cargando…

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration

PURPOSE: There is no prevention or treatment for diabetic retinal neurodegeneration (DRN), which is a complication of diabetes that can occur independently of diabetic retinopathy (DR). We hypothesized that an intravitreal fluocinolone acetonide (FAc) implant may affect the rate of DRN when used in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lynch, Stephanie K., Lee, Kyungmoo, Chen, Zhi, Folk, James C., Schmidt-Erfurth, Ursula, Gerendas, Bianca S., Wahle, Andreas, Wykoff, Charles C., Abràmoff, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2019
Materias:	Retina
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528841/ https://www.ncbi.nlm.nih.gov/pubmed/31100106 http://dx.doi.org/10.1167/iovs.18-24643

Ejemplares similares

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Inner Retinal Changes in Acute Experimental BRVO Treated With Bevacizumab or Triamcinolone Acetonide
por: McAllister, Ian L., et al.
Publicado: (2023)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)

Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections
por: McClard, Cynthia K, et al.
Publicado: (2021)

Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII)
por: Wang, Rui, et al.
Publicado: (2022)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease
por: Abramoff, Michael D., et al.
Publicado: (2018)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy
por: Tlucek, Paul S, et al.
Publicado: (2013)

Safety Profile of Lutein- Versus Triamcinolone Acetonide–Based Vitreous Staining
por: Lazzara, Francesca, et al.
Publicado: (2023)

Assessment of Detailed Photoreceptor Structure and Retinal Sensitivity in Diabetic Macular Ischemia Using Adaptive Optics-OCT and Microperimetry
por: Datlinger, Felix, et al.
Publicado: (2021)

Scleral fixation of fluocinolone acetonide implant()
por: Tabandeh, Homayoun, et al.
Publicado: (2020)

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
por: Brumm, Matthew V, et al.
Publicado: (2007)

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard, John D, et al.
Publicado: (2012)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis
por: Babel, Adrian T, et al.
Publicado: (2022)

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
por: Minnella, Angelo Maria, et al.
Publicado: (2021)

The Retinal Nerve Fiber Layer Thickness Is Associated with Systemic Neurodegeneration in Long-Term Type 1 Diabetes
por: Brock, Christina, et al.
Publicado: (2023)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
por: Coelho, João, et al.
Publicado: (2019)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries
por: Lebrize, Sarah, et al.
Publicado: (2022)

Blast Preconditioning Protects Retinal Ganglion Cells and Reveals Targets for Prevention of Neurodegeneration Following Blast-Mediated Traumatic Brian Injury
por: Harper, Matthew M., et al.
Publicado: (2019)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
por: McCluskey, Jessica D, et al.
Publicado: (2019)

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
por: Kessler, Lucy Joanne, et al.
Publicado: (2022)

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report
por: Rezkallah, Amina, et al.
Publicado: (2022)

Active Transport and Ocular Distribution of Intravitreally Injected Liposomes
por: Eriksen, Anne Zebitz, et al.
Publicado: (2023)

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection
por: Zhang, Yu, et al.
Publicado: (2018)

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes
por: Trejo Corona, Stephanie, et al.
Publicado: (2023)

Subretinal Drusenoid Deposits and Photoreceptor Loss Detecting Global and Local Progression of Geographic Atrophy by SD-OCT Imaging
por: Reiter, Gregor S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j2vc1vo1mcrh64aha15esc4sih